At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
Tri-complex inhibitors (TCIs) are molecular glues that bind to active GTP-bound RAS and recruit the intracellular chaperone cyclophilin A (CYPA) to generate a synthetic inhibitory complex that blocks ...
An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...
Shocking video captured the moments anti-ICE agitators were arrested outside Delaney Hall in Newark, New Jersey, Friday, during riotous confrontations. U.S. Department of Homeland Security Secretary ...
Late-onset Alzheimer’s disease (LOAD) accounts for over 95% of Alzheimer’s disease (AD) cases. However, modeling the age-dependent neuropathological hallmarks of LOAD has remained a major challenge.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results